Webinar: Changing the Landscape of Atrial Fibrillation Diagnostics

Can digital health decrease associated complications such as heart failure and stroke?

The prevalence of atrial fibrillation and related cardiovascular complications are a major and growing healthcare burden globally. Atrial fibrillation is considered as the most common cause for ischemic stroke which is the number one cause of long-term disability. Atrial fibrillation is also a common cause of heart failure.

Combined with the fact that atrial fibrillation is often asymptomatic, it raises the question: How can we improve the detection of atrial fibrillation in risk populations and decrease associated morbidity?

In this webinar led by Tero-Pekka Alastalo (MD, PhD), we discuss the current state of atrial fibrillation diagnostics and screening. We also address the benefits and potential disadvantages atrial fibrillation screening at scale could bring to the individual and the healthcare system.

Webinar objectives:

• Discuss the benefits and potential disadvantages of at-home monitoring and digital health solutions

• Review different technological approaches to atrial fibrillation screening

• Summarize the current clinical guidance on the topic

• Evaluate potential benefits and concerns of screening at scale in clinical practice

• Describe the benefits of utilizing CardioSignal technology in home monitoring and heart disease detection

Tero-Pekka Alastalo (MD, PhD)

Tero-Pekka Alastalo is the Chief Medical Officer and General Manager of CardioSignal’s operations in the United States. He is based in San Francisco, CA. He has an MD-PhD degree and is specialized in pediatric cardiology. He did his postdoctoral training at Stanford University School of Medicine on the molecular genetic mechanisms of cardiovascular diseases. Tero-Pekka Alastalo is a co-founder of the clinical genetic testing company Blueprint Genetics.